Synonym:EKB569;EKB-569;EKB569;WAY-172569;WAY172569;WAY172569;Pelitinib

IUPAC/ChemicalName:(E)-N-(4-((3-chloro-4-fluorophenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide

InChiKey:WVUNYSQLFKLYNI-AATRIKPKSA-N

InChiCode:InChI=1S/C24H23ClFN5O2/c1-4-33-22-12-20-17(11-21(22)30-23(32)6-5-9-31(2)3)24(15(13-27)14-28-20)29-16-7-8-19(26)18(25)10-16/h5-8,10-12,14H,4,9H2,1-3H3,(H,28,29)(H,30,32)/b6-5+

SMILESCode:O=C(NC1=C(OCC)C=C2N=CC(C#N)=C(NC3=CC=C(F)C(Cl)=C3)C2=C1)/C=C/CN(C)C

TechnicalData

AdditionalInformation

References

1:MaherHM,AlzomanNZ,ShehataSM.Aneco-friendlydirectspectrofluorimetricmethodforthedeterminationofirreversibletyrosinekinaseinhibitors,neratinibandpelitinib:applicationtostABIlitystudies.Luminescence.2016Jun1.doi:10.1002/bio.3160.PubMedPMID:27246364.

2:ToKK,PoonDC,WeiY,WangF,LinG,FuL.Pelitinib(EKB-569)targetstheup-regulationofABCB1andABCG2inducedbyhyperthermiatoerADIcatelungcancer.BrJPharmacol.2015Aug;172(16):4089-106.doi:10.1111/bph.13189.PubMedPMID:25988710;PubMedCentralPMCID:PMC4543615.

3:WiewrodtR,SerkeM,GrohéC,BrücklW.[EmployingtyrosinekinaseinhibitorsinthefirstlinetreatmentofEGFR-positivemetastaticNSCLC-stateoftheartandrecentdevelopments].Pneumologie.2013Sep;67(9):494-501.doi:10.1055/s-0033-1344337.Review.German.PubMedPMID:24006195.

4:LuethiD,DurmusS,SchinkelAH,SchellensJH,BeijnenJH,SparidansRW.Liquidchromatography-tandemmassspectrometryassayfortheEGFRinhibitorpelitinibinplasma.JChromatogrBAnalytTechnolBiomedLifeSci.2013Sep1;934:22-5.doi:10.1016/j.jchromb.2013.06.030.PubMedPMID:23892825.

5:AravindanN,AravindanS,HermanTS,NatarajanM.EGFRtyrosinekinaseinhibitorpelitinibregulatesradiation-inducedp65-dependenttelomeraseactivationinsquamouscellcarcinoma.RadiatRes.2013Mar;179(3):304-12.doi:10.1667/RR3028.1.PubMedPMID:23379415.

6:MajemM,PallarèsC.Anupdateonmolecularlytargetedtherapiesinsecond-andthird-linetreatmentinnon-smallcelllungcancer:focusonEGFRinhibitorsandanti-angiogenicagents.ClinTranslOncol.2013May;15(5):343-57.doi:10.1007/s12094-012-0964-2.Review.PubMedPMID:23359171.

7:CrabtreeJE,JeremyAH,DuvalC,DixonMF,DanjoK,CarrIM,PritchardDM,RobinsonPA.EffectsofEGFRInhibitoronHelicobacterpyloriInducedGastricEpithelialPathologyinVivo.Pathogens.2013Oct14;2(4):571-90.doi:10.3390/pathogens2040571.PubMedPMID:25437333;PubMedCentralPMCID:PMC4235704.

8:HegedüsC,Truta-FelesK,AntalffyG,VáradyG,NémetK,Ozvegy-LaczkaC,KériG,OrfiL,SzakácsG,SettlemanJ,VáradiA,SarkadiB.InteractionoftheEGFRinhibitorsgefitinib,vandetanib,pelitinibandneratinibwiththeABCG2multidrugtransporter:implicationsfortheemergenceandreversalofcancerdrugresistance.BiochemPharmacol.2012Aug1;84(3):260-7.doi:10.1016/j.bcp.2012.04.010.PubMedPMID:22548830.

9:AravindanN,ThomasCRJr,AravindanS,MohanAS,VeeraraghavanJ,NatarajanM.IrreversibleEGFRinhibitorEKB-569targetslow-LETγ-radiation-triggeredrelorchestrationandpotentiatescelldeathinsquamouscellcarcinoma.PLoSOne.2011;6(12):e29705.doi:10.1371/journal.pone.0029705.PubMedPMID:22242139;PubMedCentralPMCID:PMC3248439.

10:KimH,LimHY.NovelEGFR-TKinhibitorEKB-569inhibitshepatocellularcarcinomacellproliferationbyAKTandMAPKpathways.JKoreanMedSci.2011Dec;26(12):1563-8.doi:10.3346/jkms.2011.26.12.1563.PubMedPMID:22147992;PubMedCentralPMCID:PMC3230015.

11:BryceAH,RaoR,SarkariaJ,ReidJM,QiY,QinR,JamesCD,JenkinsRB,BoniJ,ErlichmanC,HaluskaP.PhaseIstudyoftemsirolimusincombinationwithEKB-569inpatientswithadvancedsolidtumors.InvestNewDrugs.2012Oct;30(5):1934-41.doi:10.1007/s10637-011-9742-1.PubMedPMID:21881915;PubMedCentralPMCID:PMC3816525.

12:Sánchez-MartínM,PandiellaA.DifferentialactionofsmallmoleculeHERkinaseinhibitorsonreceptorheterodimerization:therapeuticimplications.IntJCancer.2012Jul1;131(1):244-52.doi:10.1002/ijc.26358.PubMedPMID:21826647.

13:Brünner-KubathC,ShabbirW,SaferdingV,WagnerR,SingerCF,ValentP,BergerW,MarianB,ZielinskiCC,GruschM,GruntTW.ThePI3kinase/mTORblockerNVP-BEZ235overridesresistanceagainstirreversibleErbBinhibitorsinbreastcancercells.BreastCancerResTreat.2011Sep;129(2):387-400.doi:10.1007/s10549-010-1232-1.PubMedPMID:21046231.

14:LiuB,YouQD,LiZY.[SynthesisandBIOLOGicalevaluationof3-quinolinecarbonitrile-7-amidederivatives].YaoXueXueBao.2009Aug;44(8):879-84.Chinese.PubMedPMID:20055156.

15:OcañaA,AmirE.Irreversiblepan-ErbBtyrosinekinaseinhibitorsandbreastcancer:currentstatusandfuturedirections.CancerTreatRev.2009Dec;35(8):685-91.doi:10.1016/j.ctrv.2009.08.001.Review.PubMedPMID:19733440.

16:AkbulutT,RegnerKR,RomanRJ,AvnerED,FalckJR,ParkF.20-HETEactivatestheRaf/MEK/ERKpathwayinrenalepithelialcellsthroughanEGFR-andc-Src-dependentmechanism.AmJPhysiolRenalPhysiol.2009Sep;297(3):F662-70.doi:10.1152/ajprenal.00146.2009.PubMedPMID:19570883;PubMedCentralPMCID:PMC2739708.

17:GruntTW,WagnerR,GruschM,BergerW,SingerCF,MarianB,ZielinskiCC,LupuR.Interactionbetweenfattyacidsynthase-andErbB-systemsinovariancancercells.BiochemBiophysResCommun.2009Jul31;385(3):454-9.doi:10.1016/j.bbrc.2009.05.085.PubMedPMID:19467222.

18:BarlesiF,BreenD.[TargetingHERpathwayinheadandneckandthoraciccancers].BullCancer.2009;96Suppl1:S35-43.doi:10.1684/BDc.2008.0774.Review.French.PubMedPMID:19433372.

19:LaheruD,CroghanG,BukowskiR,RudekM,MessersmithW,ErlichmanC,PelleyR,JimenoA,DonehowerR,BoniJ,AbbasR,MartinsP,ZacharchukC,HidalgoM.AphaseIstudyofEKB-569incombinationwithcapecitabineinpatientswithadvancedcolorectalcancer.ClinCancerRes.2008Sep1;14(17):5602-9.doi:10.1158/1078-0432.CCR-08-0433.PubMedPMID:18765554;PubMedCentralPMCID:PMC3086427.

20:CrespoA,ZhangX,FernándezA.Redesigningkinaseinhibitorstoenhancespecificity.JMedChem.2008Aug28;51(16):4890-8.doi:10.1021/jm800453a.PubMedPMID:18680272.